Saccharomyces boulardii and Lactulose for Childhood Functional Constipation: A Multicenter Randomized Controlled Trial

다국어 초록 (Multilingual Abstract)

Background/AimsThe effects of probiotics in children vary based on diseases and probiotic strains. We aim to investigate the effectiveness of Saccharomyces boulardii and lactulose for treating childhood functional constipation.
MethodsThis open-label randomized controlled trial was conducted at 10 university hospitals in Korea. Children who were diagnosed with functional constipation were allocated to 3 groups (lactulose monotherapy, combination therapy, and S. boulardii monotherapy). The primary outcome was treatment success rate that was accordingly defined as ≥ 3 bowel movements without incontinence at week 12. The cumulative successful maintenance and drug maintenance rates without drug changes were calculated throughout the study period. We compared stool frequency, incontinence, consistency, and painful defecation at week 2 among the 3 groups.
ResultsOverall, 187 children were assigned to the lactulose monotherapy (n = 69), combination therapy (n = 68), or S. boulardii monotherapy (n = 50) groups. The primary outcome was significantly higher in the lactulose monotherapy group (26.1%) or combination therapy group (41.2%) than in the S. boulardii monotherapy group (8.0%). The S. boulardii monotherapy group showed a significantly lower cumulative successful maintenance and drug maintenance rate than the other 2 groups. There were no significant intergroup differences in the frequency of defecation, incontinence, painful defecation, or stool consistency during the follow-up at week 2.
ConclusionS. boulardii monotherapy was not superior to lactulose monotherapy or combination therapy and showed a higher drug change rate, supporting the current recommendation of probiotics in the treatment of childhood functional constipation.

참고문헌 (Reference)

1 Jakobsen JC, "When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts" 17 : 162-, 2017

2 World Health Organization, "WHO Director-General’s opening remarks at the media briefing on COVID19-11 March 2020"

3 Mancabelli L, "Unveiling the gut microbiota composition and functionality associated with constipation through metagenomic analyses" 7 : 9879-, 2017

4 Durack J, "The gut microbiome : relationships with disease and opportunities for therapy" 216 : 20-40, 2019

5 Sadeghzadeh M, "The effect of probiotics on childhood constipation : a randomized controlled double blind clinical trial" 2014 : 1-5, 2014

6 Wojtyniak K, "Systematic review : probiotics for functional constipation in children" 176 : 1155-1162, 2017

7 Akhondi-Meybodi M, "Study of the effect of probiotic Saccharomyces Boulardii on the treatment of irritable bowel syndrome" 3 : 152-156, 2014

8 Lewis SJ, "Stool form scale as a useful guide to intestinal transit time" 32 : 920-924, 1997

9 Terciolo C, "Saccharomyces boulardii CNCM I-745 restores intestinal barrier integrity by regulation of ecadherin recycling" 11 : 999-1010, 2017

10 Huang R, "Positive effect of probiotics on constipation in children : a systematic review and meta-analysis of six randomized controlled trials" 7 : 153-, 2017

11 Guerra PV, "Pediatric functional constipation treatment with Bifidobacterium-containing yogurt : a crossover, doubleblind, controlled trial" 17 : 3916-3921, 2011

12 장효정 ; 정주영 ; 서지현 ; 문진수 ; 최병호 ; 심정옥, "Nationwide Survey for Application of ROME IV Criteria and Clinical Practice for Functional Constipation in Children" 대한의학회 34 (34): 1-11, 2019

13 Coccorullo P, "Lactobacillus reuteri(DSM 17938)in infants with functional chronic constipation : a double-blind, randomized, placebo-controlled study" 157 : 598-602, 2010

14 Wojtyniak K, "Lactobacillus casei rhamnosus Lcr35 in the management of functional constipation in children : a randomized trial" 184 : 101-105, 2017

15 Bu LN, "Lactobacillus casei rhamnosus Lcr35 in children with chronic constipation" 49 : 485-490, 2007

16 Jadrešin O, "Lack of benefit of Lactobacillus reuteri DSM 17938 as an addition to the treatment of functional constipation" 67 : 763-766, 2018

17 Jadrešin O, "Lack of benefit of Lactobacillus reuteri DSM 17938 as an addition to the treatment of functional constipation" 67 : 763-766, 2018

18 Tripepi G, "Intention to treat and per protocol analysis in clinical trials" 25 : 513-517, 2020

19 Garcia Vilela E, "Influence of Saccharomyces boulardii on the intestinal permeability of patients with crohn’s disease in remission" 43 : 842-848, 2008

20 Banaszkiewicz A, "Ineffectiveness of Lactobacillus GG as an adjunct to lactulose for the treatment of constipation in children : a double-blind, placebo-controlled randomized trial" 146 : 364-369, 2005

21 Ohkusa T, "Gut microbiota and chronic constipation : a review and update" 6 : 19-, 2019

22 Tabbers MM, "Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation : a randomized, double-blind, controlled trial" 127 : e1392-e1399, 2011

23 Tabbers MM, "Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation : a randomized, double-blind, controlled trial" 127 : e1392-e1399, 2011

24 Tabbers MM, "Evaluation and treatment of functional constipation in infants and children : evidence-based recommendations from ESPGHAN and NASPGHAN" 58 : 258-274, 2014

25 Mugie SM, "Epidemiology of constipation in children and adults : a systematic review" 25 : 3-18, 2011

26 Kelesidis T, "Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders" 5 : 111-125, 2012

27 Cao H, "Dysbiosis contributes to chronic constipation development via regulation of serotonin transporter in the intestine" 7 : 10322-, 2017

28 Waller PA, "Dose-response effect of Bifidobacterium lactis HN019 on whole gut transit time and functional gastrointestinal symptoms in adults" 46 : 1057-1064, 2011

29 Abbas Z, "Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome : a randomized trial" 26 : 630-639, 2014

30 Ranganathan P, "Common pitfalls in statistical analysis : intention-to-treat versus per-protocol analysis" 7 : 144-146, 2016

31 Benninga MA, "Childhood functional gastrointestinal disorders : neonate/toddler" 150 : 1443-1455, 2016

32 Hyams JS, "Childhood functional gastrointestinal disorders : child/adolescent" 150 : 1456-1468, 2016

33 Marteau P, "Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women : a double-blind, randomized, controlled study" 16 : 587-593, 2002

34 Terciolo C, "Beneficial effects of Saccharomyces boulardii CNCM I-745 on clinical disorders associated with intestinal barrier disruption" 12 : 67-82, 2019

35 Koppen IJN, "Awareness and implementation of the 2014 ESPGHAN/NASPGHAN guideline for childhood functional constipation" 66 : 732-737, 2018